BIOMEX 1.1

Clinical Performance Study Report CPSR 2021_31

Sejoy SARS-CoV-2 Antigen Rapid Test Cassette

REF: COVG-602ST

Analytical/diagnostic specificity

Diagnostic sensitivity

Sponsor:

Hangzhou Sejoy Electronics & Instruments Co., Ltd.
Area C, Building 2, No.365, Wuzhou Road,
Yuhang Economic Development Zone,
311100 Hangzhou City, Zhejiang,
P.R.China

SEJOY®

Content

1 Purpose of the Study 3
2 Sponsor – investigation – study coordination 3
2.1 Sponsor: 3
2.2 Investigation: 3
2.3 Study Coordination: 3
3 Scope 4
3.1 Objectives 4
3.2 Study Design Type 4
3.3 Current state of the art 4
3.4 Reference Test 5
3.5 Expected Risk & benefits 5
4 Timelines 5
5 Description Device 5
5.1 Identification 5
5.2 Manufacturer if different from the sponsor 5
5.3 Intended purpose 5
5.4 Analyte or marker 5
5.5 Specimen Type 5
5.6 Metrological Traceability 5
5.7 Technical and Functional Features 5
6 Study Design 5
6.1 Materials Supplied by the manufacturer 6
6.2 Materials Supplied by the Investigator 6
6.3 Study population 6
6.4 Test procedure 7
7 Data management 8
7.1 Data and results recording 8
7.2 Data analysis 8
8 Results 8
8.1 Definitions 8
8.2 Diagnostic sensitivity 9
8.3 Diagnostic specificity 9
8.4 Analytical specificity 10
9 Conclusion 10
10 Bibliography 11
11 Annexes 11
12 Approval 12

1 Purpose of the Study

The objective of this performance study is to establish the sensitivity and specificity of the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette (REF: COVG-602ST) in order to meet the "Minimum criteria for SARS-CoV-2 antigen tests in the sense of §1 Abs. 1 Satz 1 TestVO: Antigen rapid tests" of the Paul-Ehrlich-Institut (PEI) dated 15.01.2021.

2 Sponsor – investigation – study coordination

2.1 Sponsor:

Hangzhou Sejoy Electronics & Instruments Co., Ltd.
Area C, Building 2, No.365, Wuzhou Road,
Yuhang Economic Development Zone,
311100 Hangzhou City, Zhejiang,
P.R.China
www.sejoy.com

2.2 Investigation:

Laboratories of Biomex GmbH Heidelberg
Siemensstr. 38
D-69123 Heidelberg
Germany
www.biomex.de

Mr. Maximilian Maschler
Project Lead
Biomex GmbH Heidelberg
Siemensstr. 38
D-69123 Heidelberg
Germany
Tel.: +49 6221 894669 25
e-mail: maschler@biomex.de

2.3 Study Coordination:

Dr. Heike Lukhaup
Head of validation
Biomex GmbH Heidelberg
Siemensstr. 38
D-69123 Heidelberg
Germany
Tel.: +49 6221 894669 43
e-mail: lukhaup@biomex.de

3 Scope

3.1 Objectives

The objective of this performance study was to establish the diagnostic sensitivity and diagnostic and analytical specificity of the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette (REF: COVG-602ST) in order to meet the "Minimum criteria for Rapid SARS-CoV-2 Antigen Tests Pursuant to Section 1 para 1 Sentence 1 TestVO (Statutory Test Regulation): Rapid Antigen Tests" of the Paul-Ehrlich-Institut (PEI) dated 15.01.2021.

Samples included:

- 109 persons with COVID-19 symptoms within seven days after onset of symptoms.
  The collection of the swabs was carried out in Germany with European subjects, usually the samples have been collected in the patients' home environment. No samples have been collected in hospitals.
- 300 asymptomatic persons without a concrete risk of exposure in the rapid SARS-CoV2 antigen test. The collection of the swabs was carried out in Germany with European subjects
- Examination of samples including those with a high concentration of related human coronaviruses (e.g. human coronavirus 229E, human coronavirus OC43, human coronavirus NL63, MERS coronavirus).
- Examinations on pathogen-positive samples in which the pathogen can cause analogous symptoms (e.g. influenza A, B; RSV), or could interfere with the test principle (e.g. protein A-positive Staphylococcus aureus in the case of nasal swabs as sample matrix)

3.2 Study Design Type

This retrospective study on frozen dry swab samples from COVID-19 infected and healthy donors was an observational study which aims to establish the analytical/diagnostic specificity and sensitivity of the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette (REF: COVG-602ST).
The swabs for the positive samples have been collected during the infectious phase of COVID-19 infected patients, the swabs of the negative samples have been collected from healthy donors.
All swabs were collected from anterior nasal cavity.
After collection all swabs (dry swabs) have been stored immediately at ≤-20°C.
As reference method all samples were tested with a RT-PCR system.

3.3 Current state of the art

The assays clinical performance is considered acceptable if the following requirements are met:

Diagnostic sensitivity:

Method: Parallel examination of diagnostic PCR tests and antigen tests in at least 100 persons with COVID-19 symptoms within seven days after onset of symptoms

Criterion: >80% of at least 100 unselected PCR-positive samples, positive in the SARS-CoV-2-rapid antigen test

Diagnostic specificity:

Method: Examinations of at least 100 asymptomatic persons without a concrete risk of exposure in the rapid SARS-CoV2 antigen test; clarification of any reactive samples by means of PCR.

Criterion: Specificity > 97 %

3.4 Reference Test

An analysis has been performed of the correlation between the antigen -positive/PCR-positive and the antigen-negative/PCR-negative samples with the Ct-values of the PCR. The detection rate of the antigen test (e.g. detection rate >90%) should be observed in relation to the Ct-value. However, it should be noted that the Ct-values vary between PCR tests in the case of a given concentration of the target RNA.

3.5 Expected Risk & benefits

There is no risk attributed to the patient since the evaluation is done retrospectively on frozen samples. The results obtained in this study will not be used for patient care decisions.

The risks related to the user have been reduced as far as possible by providing detailed instructions for use with the kits, including warning and precautions for the users and known limitations of the device. Furthermore, the study will be performed by professionals who are qualified and trained for conducting the clinical performance study.

4 Timelines

Starting date: 22nd of June 2021
End-date: 2nd of July 2021

5 Description Device

5.1 Identification

Sejoy SARS-CoV-2 Antigen Rapid Test Cassette

5.2 Manufacturer if different from the sponsor

Not applicable.

5.3 Intended purpose

The Sejoy SARS-CoV-2 Antigen Rapid Test Cassette is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 antigen in human nasal swabs. The identification is based on the monoclonal antibodies specific for the Nucleocapsid (N) Protein of SARS-CoV-2.It is intended to aid in the rapid differential diagnosis of COVID-19 infection.

5.4 Analyte or marker

SARS-CoV-2 antigen

5.5 Specimen Type

Anterior nasal swab

5.6 Metrological Traceability

Not applicable.

5.7 Technical and Functional Features

The Sejoy SARS-CoV-2 Antigen Rapid Test Cassette is a qualitative lateral flow immunoassay for the detection of the N protein of SARS-CoV-2 in human nasal swabs. In this assay, an antibody specific for the N protein of SARS-CoV-2 is applied separately to the test line regions of the test cassette. During the test, the extracted sample reacts with the SARS-CoV-2 N protein antibody coated on the particles. The mixture moves onto the membrane where it reacts with the SARS-CoV-2 N protein antibody and creates a colored line in the test area. The presence of this colored

line in the test area, indicates a positive result. For procedural control, a colored line always appears in the control area if the test was performed properly.

6 Study Design

6.1 Materials Supplied by the manufacturer.

6.1.1 Test Kits and Instructions for Use

Sufficient kits of the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette together with the Instructions for Use have been supplied free of charge to carry out the entire evaluation.

6.1.2 Instrument

Not applicable.

6.2 Materials Supplied by the Investigator

6.2.1 Standard laboratory reagents and disposables.

These are supplied by the Investigator and must meet the specifications required to correctly carry out the test procedure.
Sejoy SARS-CoV-2 Antigen Rapid Test Cassette used:
Lot number: COV2104001-T Expiry date: 2022-10-05

6.2.2 Equipment/Instrumentation

Nucleic acid extraction will be performed with the R-Biopharm RIDA Xtract (REF: PGZ001) and analyzed with the R-Biopharm RIDA Gene SARS-CoV-2 real-time PCR kit (REF: PG6815), with the CFX96 Touch Real-Time PCR Detection System from Bio-Rad Laboratories (Hercules, USA).

R-Biopharm RIDA Xtract Kit used:
Lot number: QL210011 Expiry date: 2022-07

R-Biopharm RIDA Gene SARS-CoV-2 real-time PCR kit used:
Lot number: 26171Z Expiry date: 2023-04

6.2.3 Samples

The samples used have been collected as dry swabs and are stored at -20°C.

6.3 Study population

According to the Minimum criteria for Rapid SARS-CoV-2 Antigen Tests the following sample numbers must be tested:

Diagnostic sensitivity:
Parallel examination of diagnostic PCR tests and antigen tests in at least 100 persons with COVID-19 symptoms within seven days after onset of symptoms

Criterion antigen test: >80% of at least 100 unselected PCR-positive samples, positive in the SARS-CoV-2-rapid antigen test.

Diagnostic specificity:
Examinations of at least 100 asymptomatic persons without a concrete risk of exposure in the rapid SARS-CoV2 antigen test; clarification of any reactive samples by means of PCR Devices shall have a specificity of > 97 %.

Required patient information:

- Collection date of swab
- Age, sex
- Date of onset of symptoms (if present)/time of infection
- Severity of symptoms (if known)

- Date of initial PCR testing (when patient was tested for the first time)
- Initial PCR result (i.e. positive or negative)

Analytical specificity

- *Potentially cross-reactive markers:*

Examination of samples including those with a high concentration of related human coronaviruses

- *human coronavirus 229E*
- *human coronavirus OC43*
- *human coronavirus NL63*
- *MERS coronavirus*

- *Potentially interfering substances:*

Examinations should also be performed on pathogen-positive samples in which the pathogen can cause analogous symptoms (e.g. influenza A, B; RSV), or could interfere with the test principle (e.g. protein A-positive Staphylococcus aureus in the case of nasal swabs as sample matrix

- *influenza A*
- *influenza B*
- *RSV*

An analysis should be performed of the correlation between the antigen -positive/PCR-positive and the antigen-negative/PCR-negative samples with the Ct-values of the PCR. In addition, the PCR protocol should be described. The mean Ct-value should be determined for the antigen-positive samples. In another evaluation, the detection rate of the antigen test (e.g. detection rate >90%) should be observed in relation to the Ct-value. However, it should again be noted that the Ct-values vary between PCR tests in the case of a given concentration of the target RNA.

6.4 Test procedure

Throughout the evaluation, all samples swabs were extracted in the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette extraction buffer as described in the IFU of the rapid test. 2-3 drops of the treated sample (approximately 90-100 µL) were applied to the sample well of the test cassette. Results obtained with the rapid test device were visually read-out by two operators between 15 and 25 minutes after the sample had been applied onto the test cassette. Digital images were taken from used rapid test cassettes after visual read-out.

Total RNA was extracted from 50 µL of the remaining liquid using the R-Biopharm RIDA Xtract (REF: PGZ001), and analyzed with the R-Biopharm RIDA Gene SARS-CoV-2 real time PCR kit (REF:PG6815).

According to a validation of different extraction volumes of 50 µl, 200 µl and 400 µl an average value of 3.14 Ct was calculated as difference between the used 50 µl and the requested 400 µl. Therefore, a Ct-value of 3.14 was subtracted from the PCR results received with 50 µl for each sample.

Real-time RT-PCR analysis was performed in singlicate analysis for all samples that were collected from infected donors and conducted using a CFX96 Touch Real-Time PCR Detection System from Bio-Rad Laboratories (Hercules, USA). The real-time RT-PCR results were obtained as Ct-values. Samples with a Ct-value of 36 (mean of the two replicates) or below were included in the calculation of the sensitivity of the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette.

7 Data management

Data management entails the planning for the creation, identification, verification, storage, transfer and archiving of data pertinent to the study, by means of the format of the study records, as well as associated responsibilities.

7.1 Data and results recording

The sample information and reference results of the samples are recorded in the Study Record Forms (SRFs) in excel.
SRF completion:

- Each item on the SRF must be completed
- No blanks can be left
- If an item is missing or not available, the entry shall be completed with 'NA'

To protect the subject or patient's privacy, no personal data shall appear anywhere on the SRF.

The data obtained with the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette are recorded on a sample sheet and as digital images taken within the prescribed time frame. The results are transferred to the SRF.

The completed SRF with sample information and reference results will be made available upon finalization of the testing.

All data will be filed both as a hard copy and in electronic files by Biomex. Data will be stored for a time period as defined in the lab's QMS procedures but at least 5 years. All laboratory results are strictly confidential.

The Sejoy SARS-CoV-2 Antigen Rapid Test Cassette results are for performance evaluation only and must not be used for diagnostic purposes.

7.2 Data analysis

The following analyses have been performed:

The diagnostic sensitivity of the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette was calculated as the number of identified positive samples compared to the total number of positive samples tested in parallel on the reference RT-PCR-assay in correlation to the Ct-value.

The diagnostic specificity of the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette was calculated as the number of negative samples on the total number of negative samples tested with the RT-PCR-test.

The diagnostic sensitivities and specificities are reported together with a 2-sided 95% confidence interval.

8 Results

8.1 Definitions

True positive sample: sample that was determined positive both using the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette and by RT-PCR.

False positive sample: sample that was determined positive using the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette, but negative by RT-PCR.

True negative sample: sample that was determined negative both using the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette and by RT-PCR.

False negative sample: sample that was determined negative using the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette but positive by RT-PCR.

Specificity (%): # true negative samples/(# true negative samples + # false positive samples) x 100

Sensitivity (%): # true positive samples/(# true positive samples + # false negative samples) x 100

8.2 Diagnostic sensitivity

In total 109 nasal swabs from donors with known SARS-CoV-2 infection were tested with the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette.

Sex, age and symptoms of the donors as well as date of onset of symptoms were known. The date of infection was presumed from indications by the donor. Date of swab collections were documented (see annex "SRF Main Evaluation Sejoy SARS-CoV-2 Antigen Rapid Test Cassette").

Analytical Results with correlation to Ct-values of the positive samples:

Ct-value	Number of Samples	Number of true positive Rapid Test Samples	Number of false negative Rapid Test Samples	Sensitivity of Sejoy SARS-CoV-2 Antigen Rapid Test Cassette (CI)
≤ 30	82	82	0	100 % (95.5-100.0%)
≤ 32	94	92	2	97.9 % (92.6-99.4%)
≤ 34	102	98	4	96.1 % (90.4-98.5%)
≤ 36	109	103	6	94.5 % (88.5-97.5%)

The correlation between the Ct-values of the analyzed samples and the sensitivity reveals a sensitivity of 97.9 % for samples with a Ct-value of up to 32. There is still a very good sensitivity of 94.5% up to a Ct-value of 36. This is in line with expectations regarding viral detection by antigen rapid testing compared to PCR analysis.
8 samples out of the 109 have been from patients with the UK mutant B.1.1.7. All samples have been detected positive with the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette, so that one can conclude that this variant is detected by this test with a very high sensitivity.

8.3 Diagnostic specificity

Samples included:
300 nasal swabs from healthy donors: Sex, age and date of sample collection were known (see annex "SRF Main Evaluation Sejoy SARS-CoV-2 Antigen Rapid Test Cassette_Annex_I").

Analytical Results with correlation to Ct-values of the negative samples:

Number of Samples	Number of true neg. Rapid Test Samples	Number of false positive Rapid Test Samples	Sensitivity of Sejoy SARS-CoV-2 Antigen Rapid Test Cassette (CI)
300	300	0	100 % (98.7-100.0)

Diagnostic Specificity of Sejoy SARS-CoV-2 Antigen Rapid Test Cassette: 100% (300/300), CI 95% CI: 98.7-100.0%

Analytical Results (Total Accuracy) for all samples with PCR result either negative or positive with a Ct-value of ≤ 36 in this study:

		RT-PCR		
		positive	negative	Total
Sejoy SARS-CoV-2 Antigen Rapid Test Cassette	positive	103	0	103
	negative	6	300	306
	total	109	300	409

Total accuracy of Sejoy SARS-CoV-2 Antigen Rapid Test Cassette: 98.5 % (403/409), CI 95% CI: 96.8-99.3%
Sensitivity of Sejoy SARS-CoV-2 Antigen Rapid Test Cassette (Ct ≤36): 94.5 % (103/109), CI: 88.5-97.5%)
Specificity of Sejoy SARS-CoV-2 Antigen Rapid Test Cassette: 100 % (300/300), CI: 98.7-100.0%

8.4 Analytical specificity

Samples included:
The following heat inactivated viruses were purchased from ZeptoMetrix Corporation, 878 Main Street, Buffalo, NY 14202:

Virus	Strain	Lot #	Exp. Date	Titer ($TCID_{50}$)
Coronavirus	229E	325111	24/09/2023	$1{,}41 \times 10^5$
Coronavirus	NL63	325222	15/10/2023	$4{,}68 \times 10^4$
Coronavirus	OC43	325491	16/11/2023	$5{,}01 \times 10^5$
MERS-CoV	Florida/USA-2_Saudi Arabia_2014	325281	20/10/2023	$1{,}17 \times 10^5$
RSV-A	2006 Isolate	324924	25/08/2023	$5{,}01 \times 10^5$
RSV-B	CH93-18(19)	325289	22/10/2023	$1{,}55 \times 10^4$
Influenza A	H1N1 New Caledonia	320943/522670	Man. 09/2018	$1{,}15 \times 10^7$
Influenza B	Yamagata/16/88	323828	25/02/2023	$5{,}62 \times 10^4$
Influenza B	Victoria/2/87	325078	23/09/2023	$1{,}70 \times 10^5$

The above listed samples were diluted with the extraction buffer provided in the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette.

Specimen	Dilution	Titer ($TCID_{50}$)
Coronavirus 229E	1:10	$1{,}41 \times 10^4$
Coronavirus NL63	1:10	$4{,}68 \times 10^3$
Coronavirus OC43	1:10	$5{,}01 \times 10^4$
MERS CoV Florida/USA-2_Saudi Arabia_2014	1:10	$1{,}17 \times 10^4$
RSV-A 2006 Isolate	1:10	$5{,}01 \times 10^4$
RSV-B CH93-18(19)	1:10	$1{,}55 \times 10^3$
Influenza A H1N1 New Caledonia	1:10	$1{,}15 \times 10^6$
Influenza B Yamagata/16/88	1:10	$5{,}62 \times 10^3$
Influenza B Victoria/2/87	1:10	$1{,}70 \times 10^4$

The $TCID_{50}$ value is converted to plaque forming units by the equation 0.69 PFU = 1 $TCID_{50}$. Example: a $TCID_{50}$ value of $1{,}15 \times 10^3$ corresponds to 794 PFU.

All dilutions were tested with the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette and found to be negative.

9 Conclusion

The specificity and sensitivity of the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette was evaluated in this study with 409 samples collected as anterior nasal swabs. All samples were tested in parallel with the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette and a real-time RT-PCR assay. Samples with a Ct-value at or below 36 were selected for the calculation of the sensitivity of the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette.

The specificity of the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette calculated from results of all samples was 100 %, the sensitivity calculated from results of samples with a Ct-value up to 32 (94

samples) was 97.9 % (95% CI: 92.6-99.4%). Also up to a Ct value of 36 the sensitivity was very good with 94.5% (95% CI: 88,5-97.5%) with only 6 negatives out of 109 samples.

In conclusion, the results from this study confirm that the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette can be used for the qualitative detection of antigen from SARS-CoV-2 in human anterior nasal swab with a very high sensitivity and specificity.

No cross-reactivity was detected with various tested viruses in the Sejoy SARS-CoV-2 Antigen Rapid Test Cassette.

10 Bibliography

- EU Regulation 2017/746 on *in vitro* Diagnostic Medical Devices
- Minimum criteria for Rapid SARS-CoV-2 Antigen Tests Pursuant to Section 1 para 1 Sentence 1 TestVO (Statutory Test Regulation): Rapid Antigen Tests " of the Paul-Ehrlich-Institut (PEI) dated 15.01.2021).
- ISO 20916 In vitro Diagnostic Medical Devices – Clinical Performance Studies using specimens form human subjects – Good Study Practices
- EU Guidance on the management of clinical trials during the COVID-19 pandemic version 3. April 2020.
- European Commission, Working document of Commission services – Current performance of COVID-19 test methods and devices and proposed performance criteria, 16 April 2020

11 Annexes

Annex I	SRF Main Evaluation Sejoy SARS-CoV-2 Antigen Rapid Test Cassette
Annex II	Pictures of positive samples
Annex III	Pictures of negative samples
Annex VI	Pictures of cross reactive samples

12 Approval

Author

Biomex GmbH	
Name:	Dr. Heike Lukhaup
Function:	Study coordinator/Principal Investigator
Date: 13.07.2021	Signature: Heike Lukhaup

Approval

Biomex GmbH	
Name:	Maximilian Maschler
Function:	Project Lead
Date: 13.07.2021	Signature: M. Maschler
Hangzhou Sejoy Electronics & Instruments Co., Ltd	
Name:	Gang Qian
Function:	Project Manager
Date: 13.07.2021	Signature: Gang Qian
Biomex GmbH	
Name:	Oliver Bošnjak
Function:	CEO
Date: 13.07.2021	Signature: O. Bošnjak

PCR Positive Results

Sample	Gender	Age	Swap date	suspected date of infection	onset symptoms	positive PCR	Time between start symptoms and swab	symptoms at time of swab taken	symptoms at time of swab taken	Comment	Test date	PCR result	Rapid test result
CA2132-NL	f	26	2021/5/21	12:30	2021/5/12	2021/5/15	2021/5/18	6	7,16,13		2021/6/24	17.47	pos
CA2095-NR	f	26	2021/5/19	21:10	2021/5/12	2021/5/15	2021/5/18	4	7,16,13,14		2021/6/22	18.02	pos
CA2487-NL	f	23	2021/5/27	23:00	2021/5/25	2021/5/26	2021/5/26	1	13,7,6,14,20,11		2021/6/24	18.89	pos
CA2133-NL	f	26	2021/5/20	17:20	2021/5/12	2021/5/15	2021/5/18	5	7,16,13,14		2021/6/24	19.00	pos
CA2186-NR	f	19	2021/5/5	10:00	n/a	2021/4/30	2021/5/3	5	13,4,7,14		2021/6/24	19.31	pos
CA2187-NL	f	19	2021/5/6	10:30	n/a	2021/4/30	2021/5/3	6	13,4,14		2021/6/24	19.71	pos
CA1319-NR	f	38	2021/3/22	20:00	2021/3/16	2021/3/21	2021/3/22	1	no Symptoms		2021/5/10	19.72	pos
CA2179-NR	f	19	2021/5/5	16:00	n/a	2021/4/30	2021/5/3	5	13,4,14		2021/6/24	19.83	pos
CA2466-NL	f	26	2021/5/21	23:00	2021/5/12	2021/5/18	2021/5/18	3	4,1,13		2021/6/24	20.27	pos
CA2102-NL	f	26	2021/5/20	22:15	2021/5/12	2021/5/15	2021/5/18	5	7,16,13		2021/6/22	20.44	pos
CA2227-NL	m	24	2021/5/2	16:22	2021/4/26	2021/4/27	2021/4/29	5	45,8,5		2021/6/24	20.75	pos
CA2066-NL	m	37	2021/5/1	21:00	2021/4/27	2021/4/27	2021/4/27	4	no Symptoms		2021/6/22	21.01	pos
CA2048-NR	m	37	2021/4/29	10:05	2021/4/27	2021/4/27	2021/4/27	2	4.15		2021/5/10	21.03	pos
CA2519-NR	f	26	2021/5/22	10:00	2021/5/12	2021/5/18	2021/5/18	4	12,4,13		2021/6/24	21.05	pos
CA1494-NL	m	50	2021/3/20	9:10	2021/3/12	2021/3/16	2021/3/17	4	13.2	UK- Mutation	2021/5/10	21.49	pos
CA2357-NR	f	23	2021/5/27	15:30	2021/5/25	2021/5/26	2021/5/26	1	13,7,6,14		2021/6/24	21.80	pos
CA1224-NL	f	44	2021/3/4	8:30	2021/2/23	2021/2/28	2021/3/1	4	7,4,2,40		2021/5/10	22.09	pos
CA1994-NL	f	10	2021/4/23	18:45	n/a	2021/4/19	2021/4/20	4	7		2021/6/22	22.26	pos
CA2168-NL	f	23	2021/5/4	22:19	2021/4/26	2021/4/27	2021/5/3	7	13,7,45,8		2021/6/24	22.60	pos
CA2077-NL	m	43	2021/5/9	21:30	2021/5/3	2021/5/6	2021/5/8	3	13,7,45,8		2021/6/22	22.87	weak pos
CA2233-NL	m	24	2021/4/30	22:22	2021/4/26	2021/4/27	2021/4/29	3	4,7,14		2021/6/24	22.94	pos
CA2366-NL	f	26	2021/5/23	17:00	2021/5/12	2021/5/18	2021/5/18	5	13.12		2021/6/24	23.08	pos
CA2215-NR	m	44	2021/5/10	21:45	n/a	2021/5/7	2021/5/8	3	14,20,32		2021/6/24	23.26	pos
CA1466-NL	m	36	2021/3/20	21:30	2021/3/13	2021/3/16	2021/3/18	4	no Symptoms	UK- Mutation	2021/5/10	23.26	pos
CA2498-NR	f	26	2021/5/23	11:00	2021/5/12	2021/5/18	2021/5/18	5	13,12,14		2021/6/24	23.27	pos
CA2346-NR	m	33	2021/5/19	17:28	2021/5/12	2021/5/17	2021/5/17	2	7		2021/6/24	23.33	pos
CA2273-NL	f	33	2021/5/4	15:25	2021/4/24	2021/4/27	2021/4/30	7	7.8		2021/6/24	23.38	pos
CA2373-NR	f	30	2021/5/20	16:10	2021/5/12	2021/5/17	2021/5/17	3	7,13,31,4,14		2021/6/24	23.44	pos
CA2177-NL	m	55	2021/4/30	19:20	2021/4/24	2021/4/28	2021/4/29	2	13,2,6,34		2021/6/24	23.46	pos
CA1487-NR	m	50	2021/3/22	20:20	2021/3/12	2021/3/16	2021/3/17	6	1.13	UK- Mutation	2021/6/22	23.73	pos
CA2269-NR	f	33	2021/5/3	23:40	2021/4/24	2021/4/27	2021/4/30	6	7.8		2021/6/24	23.93	pos
CA2054-NR	m	37	2021/4/29	13:30	2021/4/27	2021/4/27	2021/4/27	2	4.15		2021/6/22	23.94	pos
CA1500-NL	f	46	2021/3/20	13:30	2021/3/12	2021/3/16	2021/3/17	4	61,4,40,13,7	UK- Mutation	2021/6/22	24.06	pos
CA2152-NL	f	24	2021/5/14	20:15	2021/5/4	2021/5/10	2021/5/10	4	45		2021/6/24	24.42	pos
CA2481-NL	f	26	2021/5/23	22:00	2021/5/12	2021/5/18	2021/5/18	5	13		2021/6/24	24.50	pos
CA2028-NL	m	8	2021/4/28	10:00	n/a	2021/4/24	2021/4/26	4	no Symptoms		2021/6/22	25.10	pos
CA2356-NL	f	26	2021/5/22	23:00	2021/5/12	2021/5/18	2021/5/18	4	13,1,12,4		2021/6/24	25.11	pos
CA2369-NL	f	26	2021/5/24	10:00	2021/5/12	2021/5/18	2021/5/18	6	13		2021/6/24	25.12	pos
CA1432-NL	m	40	2021/3/18	7:40	2021/3/8	2021/3/15	2021/3/12	3	no Symptoms	UK- Mutation	2021/5/10	25.18	pos

PCR Positive Results

Sample	Gender	Age	Swap date	suspected date of infection	onset symptoms	positive PCR	Time between start symptoms and swab	symptoms at time of swab taken	symptoms at time of swab taken	Comment	Test date	PCR result	Rapid test result
CA2229-NL	m	24	2021/5/1	20:33	2021/4/26	2021/4/27	2021/4/29	4	4,6,14		2021/6/24	25.22	pos
CA2197-NR	m	38	2021/5/4	9:00	2021/4/24	2021/5/5	2021/4/30	-1	no Symptoms		2021/6/24	25.33	pos
CA1464-NL	f	35	2021/3/17	23:00	2021/3/8	2021/3/15	2021/3/12	2	7.46	UK- Mutation	2021/5/10	25.48	pos
CA2124-NR	f	51	2021/5/11	10:05	n/a	2021/5/5	2021/5/6	6	58,4,20,7		2021/6/24	25.56	pos
CA2134-NR	f	26	2021/5/21	12:30	2021/5/12	2021/5/16	2021/5/17	5	13,14,7		2021/6/24	25.62	pos
CA2081-NL	m	44	2021/5/12	17:15	n/a	2021/5/7	2021/5/8	5	14.11		2021/6/22	25.75	pos
CA2146-NR	m	25	2021/5/10	14:15	2021/5/4	2021/5/6	2021/5/6	4	14,13,40		2021/6/24	25.92	pos
CA2248-NL	m	38	2021/5/3	17:44	2021/4/24	2021/5/5	2021/4/30	-2	no Symptoms		2021/6/24	25.97	pos
CA2251-NR	m	38	2021/5/4	15:30	2021/4/24	2021/5/5	2021/4/30	-1	no Symptoms		2021/6/24	26.01	pos
CA2257-NR	f	33	2021/5/4	8:55	2021/4/24	2021/4/27	2021/4/30	7	7.8		2021/6/24	26.01	pos
CA2278-NL	f	31	2021/5/4	10:00	2021/4/24	2021/4/27	2021/4/27	7	7.4		2021/6/24	26.05	pos
CA1395-NL	m	56	2021/4/1	11:20	2021/3/22	2021/3/25	2021/3/26	7	7,13,4,40		2021/6/22	26.10	pos
CA0640-NL	w	42	2020/11/9	20:00	n.a.	2020/11/2	2020/11/3	7	8		2021/6/22	26.11	pos
CA2169-NR	f	23	2021/5/4	18:15	2021/4/26	2021/4/27	2021/5/3	7	13,7,45,8		2021/6/24	26.75	pos
CA2367-NR	f	30	2021/5/20	22:30	2021/5/12	2021/5/17	2021/5/17	3	7,13,31,4,14		2021/6/24	27.03	pos
CA2210-NR	m	44	2021/5/11	17:00	n/a	2021/5/7	2021/5/8	4	20,32,14,7,13		2021/6/24	27.13	pos
CA2049-NR	m	4	2021/4/29	10:33	2021/4/23	2021/4/23	2021/4/27	6	13		2021/6/22	27.19	pos
CA2343-NL	f	23	2021/5/29	9:30	2021/5/25	2021/5/26	2021/5/26	3	13,7,4,14,20		2021/6/24	27.21	pos
CA0314-NR	m	52	2020/11/6	9:25	2020/10/25	2020/10/31	2020/11/3	6	44		2021/6/22	27.34	weak pos
CA2099-NR	m	25	2021/5/11	11:35	2021/5/4	2021/5/6	2021/5/6	5	13		2021/6/22	27.43	pos
CA2116-NR	f	24	2021/5/15	20:06	2021/5/4	2021/5/10	2021/5/10	5	45,8,7		2021/6/22	27.56	weak pos
CA2118-NL	f	26	2021/5/22	12:30	2021/5/12	2021/5/15	2021/5/18	7	7,16,13		2021/6/22	27.64	pos
CA2277-NR	m	22	2021/5/5	15:30	2021/4/26	2021/4/28	2021/5/3	7	13.7		2021/6/24	27.65	weak pos
CA1997-NL	f	40	2021/4/23	19:05	2021/4/12	2021/4/16	2021/4/19	7	2		2021/6/22	27.73	pos
CA1222-NL	m	54	2021/3/6	7:45	2021/2/25	2021/2/28	2021/3/4	6	13,7,5		2021/5/10	27.86	pos
CA2175-NR	m	55	2021/5/2	21:00	2021/4/24	2021/4/28	2021/4/29	4	13,34,14		2021/5/10	28.00	pos
CA2038-NL	m	8	2021/4/26	21:00	n/a	2021/4/24	2021/4/26	2	7		2021/5/10	28.00	pos
CA2034-NR	m	8	2021/4/27	10:45	n/a	2021/4/24	2021/4/26	3	no Symptoms		2021/6/22	28.01	very weak pos
CA1344-NL	m	36	2021/3/23	8:45	n/a	2021/3/17	2021/3/18	6	2.32		2021/5/10	28.05	pos
CA2020-NR	f	12	2021/4/26	15:15	n/a	2021/4/24	2021/4/26	2	7.4		2021/5/10	28.13	pos
CA2067-NL	f	8	2021/4/30	13:40	n/a	2021/4/27	2021/4/27	3	14.4		2021/6/22	28.14	weak pos
CA2480-NR	f	23	2021/5/28	15:15	2021/5/25	2021/5/26	2021/5/26	2	13,7,4,14,20		2021/6/24	28.15	pos
CA2136-NR	f	19	2021/5/10	20:05	2021/5/5	2021/5/5	2021/5/6	5	7,4,45		2021/6/24	28.29	weak pos
CA2497-NR	m	33	2021/5/20	22:30	2021/5/12	2021/5/17	2021/5/17	3	7		2021/6/24	28.37	weak pos
CA2279-NL	f	31	2021/5/3	22:45	2021/4/24	2021/4/27	2021/4/27	6	4		2021/6/24	28.47	pos
CA1468-NL	f	40	2021/3/18	18:00	2021/3/6	2021/3/13	2021/3/15	5	54,13,14	UK- Mutation	2021/5/10	28.52	pos
CA1416-NL	f	38	2021/3/22	20:30	n/a	2021/3/16	2021/3/17	6	13,7,45,8		2021/6/22	28.81	pos
CA1996-NR	m	43	2021/5/7	22:45	2021/5/3	2021/5/6	2021/5/8	1	1,2,7		2021/6/22	28.88	neg
CA1379-NL	m	20	2021/3/30	17:00	2021/3/23	2021/3/24	2021/3/26	6	4.2		2021/6/22	28.91	pos

PCR Positive Results

Sample	Gender	Age	Swap date	suspected date of infection	onset symptoms	positive PCR	Time between start symptoms and swab	symptoms at time of swab taken	symptoms at time of swab taken	Comment	Test date	PCR result	Rapid test result
CA2467-NR	f	26	2021/5/24	16:00	2021/5/12	2021/5/18	2021/5/18	6	13.1		2021/6/24	29.12	weak pos
CA1505-NR	f	46	2021/3/20	20:30	2021/3/12	2021/3/16	2021/3/17	4	13,4,7	UK- Mutation	2021/5/10	29.86	pos
CA2065-NR	f	8	2021/4/29	10:20	n/a	2021/4/27	2021/4/27	2	14		2021/5/10	29.95	pos
CA2461-NR	m	22	2021/5/20	18:52	2021/5/12	2021/5/15	2021/5/18	5	13.7		2021/6/24	30.29	weak pos
CA2496-NL	m	33	2021/5/21	11:30	2021/5/12	2021/5/17	2021/5/17	4	7		2021/6/24	30.52	weak pos
CA2511-NL	f	30	2021/5/22	22:30	2021/5/12	2021/5/17	2021/5/17	5	13.7		2021/6/24	30.72	weak pos
CA2336-NL	m	33	2021/5/20	16:30	2021/5/12	2021/5/17	2021/5/17	3	7		2021/6/24	30.82	weak pos
CA1348-NR	m	36	2021/3/24	11:00	n/a	2021/3/17	2021/3/18	7	2.32		2021/6/22	30.91	pos
CA2345-NL	f	30	2021/5/21	16:10	2021/5/12	2021/5/17	2021/5/17	4	13.7		2021/6/24	30.98	weak pos
CA1417-NL	f	38	2021/3/23	20:15	n/a	2021/3/16	2021/3/17	7	7,13,45,8,40,54,52		2021/6/22	31.03	weak pos
CA1006-NR	w	25	2020/12/15	8:45	2020/12/3	2020/12/8	2020/12/8	7	7.8		2021/6/22	31.20	neg
CA2035-NR	m	8	2021/4/30	12:00	n/a	2021/4/24	2021/4/26	6	no Symptoms		2021/6/22	31.57	neg
CA2243-NL	m	38	2021/5/5	23:45	2021/4/24	2021/5/5	2021/4/30	0	4		2021/6/24	32.19	very weak pos
CA0916-NR	w	51	2020/11/30	20:00	2020/11/17	2020/11/24	2020/11/26	6	1		2021/6/22	32.26	weak pos
CA0987-NL	m	24	2020/12/10	11:00	2020/11/28	2020/12/3	2020/12/4	7	no Symptoms		2021/6/22	32.30	weak pos
CA1999-NR	f	10	2021/4/24	12:30	n/a	2021/4/19	2021/4/20	5	7		2021/6/22	32.46	pos
CA0547-NR	w	51	2020/11/30	10:00	2020/11/17	2020/11/24	2020/11/26	6	1		2021/6/22	33.02	weak pos
CA2120-NL	f	24	2021/5/19	16:29	2021/5/13	2021/5/16	2021/5/17	3	45,14,15,4		2021/6/24	33.03	weak pos
CA1388-NR	f	20	2021/3/30	21:26	2021/3/21	2021/3/23	2021/3/25	7	13,45,8,29		2021/6/22	33.88	pos
CA1992-NR	f	10	2021/4/25	18:15	n/a	2021/4/19	2021/4/20	6	7		2021/6/22	34.16	neg
CA2493-NL	m	33	2021/5/22	16:30	2021/5/12	2021/5/17	2021/5/17	5	no Symptoms		2021/6/24	34.31	neg
CA0699-NR	m	49	2020/11/16	19:00	2020/11/8	2020/11/9	2020/11/10	7	8,45,4		2021/6/22	34.36	weak pos
CA2340-NL	m	33	2021/5/19	17:25	2021/5/12	2021/5/17	2021/5/17	2	7		2021/6/24	34.44	weak pos
CA0040-NL	m	66	2020/10/31	17:50	2020/10/22	2020/10/25		6	13.7		2021/6/22	34.47	very weak pos
CA0964-NL	w	57	2020/12/8	11:00	2020/11/27	2020/12/1	2020/12/3	7	13		2021/6/22	34.58	very weak pos
CA0898-NL	m	38	2020/12/2	9:30	2020/11/23	2020/11/26	2020/11/27	6	8.45		2021/6/22	34.65	weak pos
CA1375-NL	m	36	2021/2/23	11:55	2021/2/13	2021/2/24	2021/2/19	-1	no Symptoms		2021/5/10	34.82	weak pos
CA2122-NR	f	26	2021/5/23	14:15	2021/5/12	2021/5/16	2021/5/17	7	13,14,7		2021/6/24	34.86	very weak pos
CA0037-NR	m	31	2020/11/1	20:15	2020/10/21	2020/10/25	020/01.11.2020	7	8,13,5,45		2021/5/10	34.87	pos
CA2119-NR	f	24	2021/5/17	9:30	2021/5/4	2021/5/10	2021/5/10	7	7		2021/6/24	35.76	neg
CA0895-NL	w	23	2020/12/1	23:00	2020/11/23	2020/11/24	2020/11/24	7	13,7,8,45		2021/6/22	36.14	neg

Symptome List

Number	Symptome
1	fever
2	limp pain
3	muscle pain
4	headache
5	backache
6	shivers
7	catarrh
8	anosmia
9	ache when swallowing
10	mucous
11	diarrhoea
12	breathing difficulties
13	coughing
14	tiredness
15	sore throat
16	sinusitis
17	pneumonia
18	chest pain
19	tachycardia
20	sickness
21	lymph node swelling
22	pressure on chest
23	Conjunctivitis (Bindehautentzündung)
24	flu-like symptoms
25	blood circulation problems
26	dry respiratory tract
27	dry skin
28	sweating
29	stomach pain
30	muscle cramps
31	hoarseness
32	loss of appetite
33	nose bleed
34	sneezing
35	confused
36	constibation
37	eye problems
38	rash
39	gastrointestinal problems
40	dizziness
41	coma
42	hospitalized
43	pain while breathing
44	smell irritation
45	loss of taste

PCR Negative Results

Sample ID	Swab date	Age	Sex	Date of PCR	PCR result	Rapid test result
CA1057	2021/2/15	22	m	2021/2/23	neg	neg
CA1074	2021/2/15	59	m	2021/3/16	neg	neg
CA1079	2021/2/16	61	m	2021/2/23	neg	neg
CA1081	2021/2/16	59	w	2021/2/23	neg	neg
CA1106	2021/1/19	16	w	2021/2/12	neg	neg
CA1117	2021/1/19	11	m	2021/2/12	neg	neg
CA1119	2021/1/19	18	m	2021/2/12	neg	neg
CA1129	2021/1/25	62	m	2021/3/17	neg	neg
CA1132	2021/1/20	16	m	2021/2/12	neg	neg
CA1135	2021/1/20	24	w	2021/2/12	neg	neg
CA1136	2021/1/20	18	m	2021/2/12	neg	neg
CA1137	2021/1/22	17	m	2021/2/11	neg	neg
CA1138	2021/1/20	67	w	2021/2/12	neg	neg
CA1139	2021/1/22	13	w	2021/2/11	neg	neg
CA1140	2021/1/20	17	m	2021/2/12	neg	neg
CA1141	2021/1/22	17	m	2021/2/11	neg	neg
CA1142	2021/1/20	44	w	2021/2/12	neg	neg
CA1143	2021/1/23	27	w	2021/2/11	neg	neg
CA1144	2021/1/20	47	w	2021/2/12	neg	neg
CA1145	2021/1/20	14	w	2021/2/12	neg	neg
CA1146	2021/1/22	26	m	2021/2/11	neg	neg
CA1147	2021/1/22	30	w	2021/2/12	neg	neg
CA1148	2021/1/21	21	w	2021/2/12	neg	neg
CA1149	2021/1/22	21	w	2021/2/12	neg	neg
CA1150	2021/1/21	22	w	2021/2/12	neg	neg
CA1151	2021/1/21	21	w	2021/2/12	neg	neg
CA1152	2021/1/21	26	w	2021/2/12	neg	neg
CA1154	2021/1/21	28	w	2021/2/12	neg	neg

PCR Negative Results

Sample ID	Swab date	Age	Sex	Date of PCR	PCR result	Rapid test result
CA1155	2021/1/22	33	m	2021/2/12	neg	neg
CA1156	2021/1/21	27	m	2021/2/12	neg	neg
CA1158	2021/1/21	30	w	2021/2/12	neg	neg
CA1160	2021/1/25	57	m	2021/2/11	neg	neg
CA1162	2021/1/21	18	w	2021/2/12	neg	neg
CA1163	2021/1/21	58	m	2021/2/11	neg	neg
CA1164	1900/1/23	23	w	2021/2/11	neg	neg
CA1166	2021/1/25	24	w	2021/2/11	neg	neg
CA1167	2021/1/25	36	m	2021/2/11	neg	neg
CA1409	2021/3/10	28	w	2021/3/16	neg	neg
CA1410	2021/3/10	27	w	2021/3/16	neg	neg
CA1626	2021/4/15	52	w	2021/5/8	neg	neg
CA1627	2021/4/16	24	w	2021/5/8	neg	neg
CA1628	2021/4/21	24	m	2021/5/11	neg	neg
CA1629	2021/4/17	28	w	2021/5/8	neg	neg
CA1630	2021/4/17	36	m	2021/5/8	neg	neg
CA1631	2021/4/17	29	w	2021/5/8	neg	neg
CA1632	2021/4/17	24	w	2021/5/8	neg	neg
CA1633	2021/4/18	50	w	2021/5/8	neg	neg
CA1634	2021/4/18	36	m	2021/5/8	neg	neg
CA1635	2021/4/16	30	w	2021/5/8	neg	neg
CA1636	2021/4/18	61	w	2021/5/8	neg	neg
CA1637	2021/4/18	28	w	2021/5/8	neg	neg
CA1638	2021/4/19	36	m	2021/5/8	neg	neg
CA1639	2021/4/16	52	w	2021/5/8	neg	neg
CA1640	2021/4/23	24	w	2021/5/11	neg	neg
CA1641	2021/4/16	36	m	2021/5/8	neg	neg
CA1642	2021/4/22	24	m	2021/5/11	neg	neg

PCR Negative Results

Sample ID	Swab date	Age	Sex	Date of PCR	PCR result	Rapid test result
CA1643	2021/4/16	58	m	2021/5/8	neg	neg
CA1644	2021/4/18	24	w	2021/5/8	neg	neg
CA1645	2021/4/18	29	w	2021/5/8	neg	neg
CA1646	2021/4/17	52	w	2021/5/8	neg	neg
CA1647	2021/4/17	30	w	2021/5/8	neg	neg
CA1648	2021/4/18	36	m	2021/5/8	neg	neg
CA1649	2021/4/18	36	m	2021/5/8	neg	neg
CA1650	2021/4/18	35	m	2021/5/8	neg	neg
CA1651	2021/4/16	35	m	2021/5/8	neg	neg
CA1652	2021/4/16	63	w	2021/5/8	neg	neg
CA1653	2021/4/16	29	w	2021/5/8	neg	neg
CA1654	2021/4/16	26	m	2021/5/8	neg	neg
CA1655	2021/4/16	36	w	2021/5/8	neg	neg
CA1666	2021/4/18	32	w	2021/5/8	neg	neg
CA1668	2021/4/17	29	w	2021/5/8	neg	neg
CA1669	2021/4/17	31	m	2021/5/8	neg	neg
CA1670	2021/4/17	76	m	2021/5/8	neg	neg
CA1671	2021/4/18	34	w	2021/5/8	neg	neg
CA1672	2021/4/18	32	m	2021/5/8	neg	neg
CA1673	n.a	n.a	n.a	2021/5/8	neg	neg
CA1674	2021/4/18	30	w	2021/5/8	neg	neg
CA1675	2021/4/17	26	m	2021/5/8	neg	neg
CA1676	2021/4/17	50	w	2021/5/8	neg	neg
CA1677	2021/4/16	50	w	2021/5/8	neg	neg
CA1678	2021/4/16	62	m	2021/5/8	neg	neg
CA1679	2021/4/21	34	w	2021/5/8	neg	neg
CA1680	2021/4/18	36	w	2021/5/8	neg	neg
CA1681	2021/4/18	29	w	2021/5/8	neg	neg

PCR Negative Results

Sample ID	Swab date	Age	Sex	Date of PCR	PCR result	Rapid test result
CA1682	2021/4/15	34	w	2021/5/8	neg	neg
CA1684	2021/4/17	58	m	2021/5/8	neg	neg
CA1685	2021/4/18	37	m	2021/5/8	neg	neg
CA1686	2021/4/16	50	w	2021/5/8	neg	neg
CA1687	2021/4/18	76	m	2021/5/8	neg	neg
CA1688	2021/4/15	32	m	2021/5/8	neg	neg
CA1689	2021/4/18	31	m	2021/5/8	neg	neg
CA1690	2021/4/17	29	w	2021/5/8	neg	neg
CA1691	2021/4/16	29	w	2021/5/8	neg	neg
CA1692	2021/4/19	29	w	2021/5/8	neg	neg
CA1693	2021/4/19	32	m	2021/5/8	neg	neg
CA1694	2021/4/18	57	w	2021/5/8	neg	neg
CA1695	2021/4/16	61	w	2021/5/8	neg	neg
CA1696	2021/4/17	57	w	2021/5/8	neg	neg
CA1697	2021/4/19	63	w	2021/5/8	neg	neg
CA1708	2021/4/15	50	w	2021/5/8	neg	neg
CA1710	2021/4/17	37	m	2021/5/8	neg	neg
CA1712	2021/4/17	62	m	2021/5/8	neg	neg
CA1713	2021/4/19	31	m	2021/5/8	neg	neg
CA1714	2021/4/17	36	m	2021/5/8	neg	neg
CA1715	2021/4/17	32	m	2021/5/8	neg	neg
CA1717	2021/4/15	63	w	2021/5/8	neg	neg
CA1719	2021/4/18	50	w	2021/5/8	neg	neg
CA1720	2021/4/18	62	m	2021/5/8	neg	neg
CA1721	2021/4/16	32	m	2021/5/8	neg	neg
CA1722	2021/4/17	32	w	2021/5/8	neg	neg
CA1723	2021/4/16	57	w	2021/5/8	neg	neg
CA1724	2021/4/17	61	w	2021/5/8	neg	neg

PCR Negative Results

Sample ID	Swab date	Age	Sex	Date of PCR	PCR result	Rapid test result
CA1725	2021/4/17	76	m	2021/5/8	neg	neg
CA1728	2021/4/16	28	w	2021/5/8	neg	neg
CA1729	2021/4/16	29	m	2021/5/8	neg	neg
CA1730	2021/4/19	25	w	2021/5/8	neg	neg
CA1731	2021/4/18	34	m	2021/5/8	neg	neg
CA1732	2021/4/18	23	w	2021/5/8	neg	neg
CA1733	2021/4/18	67	m	2021/5/8	neg	neg
CA1734	2021/4/21	37	w	2021/5/8	neg	neg
CA1735	2021/4/18	27	w	2021/5/8	neg	neg
CA1736	2021/4/20	18	m	2021/5/8	neg	neg
CA1737	2021/4/19	65	w	2021/5/8	neg	neg
CA1738	2021/4/17	25	m	2021/5/8	neg	neg
CA1739	2021/4/17	19	m	2021/5/8	neg	neg
CA1740	2021/4/18	31	w	2021/5/8	neg	neg
CA1741	2021/4/18	27	m	2021/5/8	neg	neg
CA1742	2021/4/19	37	w	2021/5/8	neg	neg
CA1743	2021/4/18	29	m	2021/5/8	neg	neg
CA1744	2021/4/20	57	w	2021/5/8	neg	neg
CA1745	2021/4/17	52	w	2021/5/8	neg	neg
CA1746	2021/4/20	27	w	2021/5/8	neg	neg
CA1747	2021/4/20	67	m	2021/5/8	neg	neg
CA1748	2021/4/18	25	m	2021/5/8	neg	neg
CA1749	2021/4/21	55	m	2021/5/8	neg	neg
CA1750	2021/4/20	37	w	2021/5/8	neg	neg
CA1751	2021/4/16	23	w	2021/5/8	neg	neg
CA1752	2021/4/19	34	m	2021/5/8	neg	neg
CA1753	2021/4/17	28	w	2021/5/8	neg	neg
CA1754	2021/4/18	65	w	2021/5/8	neg	neg

PCR Negative Results

Sample ID	Swab date	Age	Sex	Date of PCR	PCR result	Rapid test result
CA1756	2021/4/17	31	m	2021/5/8	neg	neg
CA1757	2021/4/17	29	m	2021/5/8	neg	neg
CA1758	2021/4/16	27	m	2021/5/8	neg	neg
CA1759	2021/4/20	65	w	2021/5/8	neg	neg
CA1760	2021/4/18	28	w	2021/5/8	neg	neg
CA1762	2021/4/18	23	m	2021/5/11	neg	neg
CA1763	2021/4/18	29	w	2021/5/8	neg	neg
CA1764	2021/4/20	34	m	2021/5/8	neg	neg
CA1765	2021/4/19	67	m	2021/5/8	neg	neg
CA1766	2021/4/20	27	m	2021/5/8	neg	neg
CA1767	2021/4/17	23	w	2021/5/8	neg	neg
CA1768	2021/4/20	30	m	2021/5/11	neg	neg
CA1778	2021/4/19	58	w	2021/6/29	neg	neg
CA1779	2021/4/17	43	w	2021/5/11	neg	neg
CA1781	2021/4/19	67	w	2021/5/11	neg	neg
CA1782	2021/4/17	33	m	2021/5/11	neg	neg
CA1783	2021/4/16	52	w	2021/5/8	neg	neg
CA1784	2021/4/17	57	m	2021/5/11	neg	neg
CA1785	2021/4/17	30	w	2021/5/11	neg	neg
CA1786	2021/4/17	50	m	2021/5/11	neg	neg
CA1787	2021/4/16	43	w	2021/5/11	neg	neg
CA1788	2021/4/18	22	w	2021/5/11	neg	neg
CA1789	2021/4/20	29	w	2021/6/29	neg	neg
CA1790	2021/4/18	31	m	2021/6/29	neg	neg
CA1791	2021/4/18	27	w	2021/6/29	neg	neg
CA1792	2021/4/18	24	w	2021/5/11	neg	neg
CA1793	2021/4/17	27	w	2021/6/29	neg	neg
CA1794	2021/4/21	30	w	2021/5/11	neg	neg

PCR Negative Results

Sample ID	Swab date	Age	Sex	Date of PCR	PCR result	Rapid test result
CA1795	2021/4/21	58	w	2021/6/29	neg	neg
CA1796	2021/4/21	18	m	2021/5/8	neg	neg
CA1797	2021/4/20	19	m	2021/5/8	neg	neg
CA1798	2021/4/19	23	m	2021/5/11	neg	neg
CA1799	2021/4/22	55	m	2021/5/8	neg	neg
CA1800	2021/4/20	22	w	2021/5/11	neg	neg
CA1801	2021/4/17	50	w	2021/5/11	neg	neg
CA1802	2021/4/17	31	m	2021/6/29	neg	neg
CA1803	2021/4/18	33	m	2021/5/11	neg	neg
CA1804	2021/4/20	23	w	2021/5/11	neg	neg
CA1805	2021/4/20	67	w	2021/5/11	neg	neg
CA1806	2021/4/18	29	w	2021/6/29	neg	neg
CA1809	2021/4/18	30	w	2021/5/11	neg	neg
CA1810	2021/4/19	18	m	2021/5/8	neg	neg
CA1812	2021/4/18	43	w	2021/5/11	neg	neg
CA1813	2021/4/18	30	w	2021/5/11	neg	neg
CA1814	2021/4/18	58	w	2021/5/11	neg	neg
CA1815	2021/4/18	50	m	2021/5/11	neg	neg
CA1816	2021/4/20	23	m	2021/5/11	neg	neg
CA1818	2021/4/21	30	m	2021/5/11	neg	neg
CA1819	2021/4/19	19	m	2021/5/8	neg	neg
CA1820	2021/4/18	23	w	2021/5/11	neg	neg
CA1821	2021/4/16	57	m	2021/5/11	neg	neg
CA1822	2021/4/18	57	w	2021/5/8	neg	neg
CA1823	2021/4/20	42	w	2021/5/11	neg	neg
CA1828	2021/4/16	33	m	2021/5/11	neg	neg
CA1829	2021/4/16	23	w	2021/6/29	neg	neg
CA1830	2021/4/20	54	w	2021/5/11	neg	neg

PCR Negative Results

Sample ID	Swab date	Age	Sex	Date of PCR	PCR result	Rapid test result
CA1831	2021/4/17	30	w	2021/5/11	neg	neg
CA1833	2021/4/18	57	m	2021/5/11	neg	neg
CA1834	2021/4/17	23	w	2021/6/29	neg	neg
CA1835	2021/4/16	50	m	2021/5/11	neg	neg
CA1836	2021/4/18	30	w	2021/5/11	neg	neg
CA1837	2021/4/19	47	m	2021/5/11	neg	neg
CA1838	2021/4/16	31	m	2021/6/29	neg	neg
CA1840	2021/4/18	47	m	2021/5/11	neg	neg
CA1841	2021/4/19	42	w	2021/5/11	neg	neg
CA1842	2021/4/19	22	w	2021/5/11	neg	neg
CA1843	2021/4/18	30	m	2021/5/11	neg	neg
CA1844	2021/4/16	30	w	2021/5/11	neg	neg
CA1845	2021/4/20	47	m	2021/5/11	neg	neg
CA1846	2021/4/16	30	w	2021/5/11	neg	neg
CA1848	2021/4/20	50	w	2021/5/11	neg	neg
CA1850	2021/4/16	58	w	2021/5/11	neg	neg
CA1851	2021/4/18	27	w	2021/5/11	neg	neg
CA1852	2021/4/17	24	w	2021/5/11	neg	neg
CA1853	2021/4/18	54	w	2021/5/11	neg	neg
CA1854	2021/4/21	30	w	2021/5/11	neg	neg
CA1855	2021/4/20	27	w	2021/5/11	neg	neg
CA1857	2021/4/21	51	w	2021/6/29	neg	neg
CA1858	2021/4/18	49	w	2021/5/11	neg	neg
CA1859	2021/4/19	49	w	2021/5/11	neg	neg
CA1860	2021/4/20	49	w	2021/5/11	neg	neg
CA1863	2021/4/18	67	w	2021/5/11	neg	neg
CA1866	2021/4/17	58	w	2021/5/11	neg	neg
CA1867	2021/4/16	24	w	2021/5/11	neg	neg

PCR Negative Results

Sample ID	Swab date	Age	Sex	Date of PCR	PCR result	Rapid test result
CA1868	2021/4/21	11	m	2021/5/11	neg	neg
CA1870	2021/4/22	36	w	2021/5/8	neg	neg
CA1871	2021/4/23	60	w	2021/5/11	neg	neg
CA1872	2021/4/24	10	m	2021/5/11	neg	neg
CA1873	2021/4/22	19	w	2021/5/11	neg	neg
CA1874	2021/4/22	36	w	2021/5/11	neg	neg
CA1875	2021/4/23	23	m	2021/5/8	neg	neg
CA1876	2021/4/23	58	m	2021/5/11	neg	neg
CA1878	2021/4/22	11	m	2021/5/11	neg	neg
CA1879	2021/4/20	38	m	2021/6/29	neg	neg
CA1880	2021/4/22	25	w	2021/6/29	neg	neg
CA1881	2021/4/23	24	w	2021/5/11	neg	neg
CA1882	2021/4/21	25	w	2021/5/11	neg	neg
CA1883	2021/4/23	45	w	2021/5/11	neg	neg
CA1884	2021/4/25	46	m	2021/5/11	neg	neg
CA1885	2021/4/20	36	w	2021/5/8	neg	neg
CA1886	2021/4/22	30	w	2021/5/11	neg	neg
CA1887	2021/4/25	25	m	2021/6/29	neg	neg
CA1888	2021/4/22	41	w	2021/5/11	neg	neg
CA1889	2021/4/20	36	w	2021/5/11	neg	neg
CA1890	2021/4/21	38	m	2021/6/29	neg	neg
CA1892	2021/4/22	16	w	2021/5/11	neg	neg
CA1893	2021/4/23	25	m	2021/6/29	neg	neg
CA1895	2021/4/22	62	m	2021/5/11	neg	neg
CA1896	2021/4/24	33	w	2021/5/11	neg	neg
CA1897	2021/4/21	15	m	2021/6/29	neg	neg
CA1898	2021/4/23	19	w	2021/5/11	neg	neg
CA1899	2021/4/21	36	w	2021/5/11	neg	neg

PCR Negative Results

Sample ID	Swab date	Age	Sex	Date of PCR	PCR result	Rapid test result
CA1900	2021/4/23	35	m	2021/5/11	neg	neg
CA1902	2021/4/21	19	w	2021/5/11	neg	neg
CA1903	2021/4/21	24	w	2021/5/11	neg	neg
CA1905	2021/4/23	16	w	2021/5/11	neg	neg
CA1908	2021/4/25	10	m	2021/5/11	neg	neg
CA1909	2021/4/22	60	w	2021/5/11	neg	neg
CA1910	2021/4/23	29	m	2021/5/11	neg	neg
CA1911	2021/4/22	27	w	2021/5/11	neg	neg
CA1912	2021/4/21	35	m	2021/5/11	neg	neg
CA1913	2021/4/21	25	w	2021/6/29	neg	neg
CA1914	2021/4/21	41	w	2021/5/11	neg	neg
CA1915	2021/4/23	36	w	2021/5/11	neg	neg
CA1916	2021/4/23	46	m	2021/5/11	neg	neg
CA1917	2021/4/21	37	m	2021/5/11	neg	neg
CA1919	2021/4/22	25	w	2021/5/11	neg	neg
CA1920	2021/4/20	41	w	2021/5/11	neg	neg
CA1922	2021/4/23	21	w	2021/5/11	neg	neg
CA1923	2021/4/26	10	m	2021/5/11	neg	neg
CA1924	2021/4/22	29	m	2021/5/11	neg	neg
CA1926	2021/4/22	19	w	2021/5/11	neg	neg
CA1928	2021/4/23	30	w	2021/5/11	neg	neg
CA1929	2021/4/21	27	w	2021/5/11	neg	neg
CA1930	2021/4/22	31	m	2021/6/29	neg	neg
CA1931	2021/4/21	59	m	2021/5/11	neg	neg
CA1932	2021/4/22	23	m	2021/5/8	neg	neg
CA1933	2021/4/22	57	m	2021/5/11	neg	neg
CA1935	2021/4/21	21	w	2021/5/11	neg	neg
CA1936	2021/4/22	46	m	2021/5/11	neg	neg

PCR Negative Results

Sample ID	Swab date	Age	Sex	Date of PCR	PCR result	Rapid test result
CA1938	2021/4/23	37	m	2021/5/11	neg	neg
CA1939	2021/4/22	37	m	2021/5/11	neg	neg
CA1940	2021/4/22	21	w	2021/5/11	neg	neg
CA1941	2021/4/21	46	m	2021/5/11	neg	neg
CA1943	2021/4/21	16	w	2021/5/11	neg	neg
CA1944	2021/4/23	31	m	2021/6/29	neg	neg
CA1946	2021/4/22	24	w	2021/5/11	neg	neg
CA1947	2021/4/22	18	m	2021/5/11	neg	neg
CA1948	2021/4/24	46	m	2021/5/11	neg	neg
CA1951	2021/4/21	57	m	2021/5/11	neg	neg
CA1953	2021/4/25	33	w	2021/5/11	neg	neg
CA1955	2021/4/21	45	w	2021/5/11	neg	neg
CA1956	2021/4/22	36	w	2021/5/11	neg	neg
CA1958	2021/4/21	60	w	2021/5/11	neg	neg
CA1959	2021/4/21	61	m	2021/5/11	neg	neg
CA1962	2021/4/22	52	w	2021/6/29	neg	neg
CA1963	2021/4/26	33	w	2021/5/11	neg	neg
CA1978	2021/4/23	18	m	2021/5/11	neg	neg
CA1984	2021/4/21	36	w	2021/5/11	neg	neg
CA1986	2021/4/23	61	m	2021/5/11	neg	neg